Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.63 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 2/20 | 0.63 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.63 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.63 |
| ▸ | DPP4 | P27487 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.63 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.63 |
| ▸ | GAPDH | P04406 | 1/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | STAT6 | P42226 | 1/20 | 0.63 |
| ▸ | PI4KA | P42356 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.63 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.63 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.63 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.63 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL2221271 | 0.96 | ADORA1 (0.60) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL16762258 | 0.88 | P2RY2 (0.63) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL9419203 | 0.85 | ADORA1 (0.63) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL10980572 | 0.85 | ADORA1 (0.74) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL28057366 | 0.85 | ADORA1 (0.67) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL27686613 | 0.85 | P2RY2 (0.65) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL26612876 | 0.83 | ADORA3 (0.72) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL2327105 | 0.83 | ADORA3 (0.72) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL28186074 | 0.83 | P2RY2 (0.80) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 | |
| Adenosine SCHEMBL30301161 | 0.82 | ADORA1 (0.81) | ADORA1SMN1; SMN2ADORA3DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241416-A1 | METHODS FOR THE IDENTIFICATION OF SARM1 NADASE ACTIVITY INHIBITORS AND USES THEREOF | UNIV BAR ILAN (US) | 2022-08-04 | — | — | US | claimed |
| EP-4592305-A2 | PRODUCTION OF CYCLIC ADENYLATES AND THEIR USE AS ALLOSTERIC REGULATORS | Vilnius University (LT) | 2025-07-30 | — | — | EP | disclosed |
| US-12370209-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| WO-2025122455-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) FOR VEGF MODULATION | INVIRSA, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250161343-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | INVIRSA, INC. (US) | 2025-05-22 | — | — | US | disclosed |
| EP-3630966-B1 | PRODUCTION OF CYCLIC ADENYLATES AND THEIR USE AS ALLOSTERIC REGULATORS | UNIV VILNIUS (LT) | 2025-04-23 | — | — | EP | disclosed |
| US-12233083-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | INVIRSA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250020654-A1 | SCREENING METHODS FOR PARP MODULATORS | RIBON THERAPEUTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| US-12123031-B2 | Regulation of CRISPR-associated rossman fold (CARF) domain containing proteins by oligoadenylates | VILNIUS UNIVERSITY (LT) | 2024-10-22 | — | — | US | disclosed |
| US-20240229012-A9 | SITE-SPECIFIC GENOME MODIFICATION TECHNOLOGY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-07-11 | — | — | US | disclosed |
| US-20030153559-A1 | Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof , and pharmaceutical compositions containing the same | N-GENE RESEARCH LABORATORIES INC. | 2003-08-14 | — | — | US | disclosed |
| EP-1154998-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | Klinge Pharma GmbH (DE) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050399-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | KLINGE PHARMA GMBH (DE) | 2000-08-31 | — | — | WO | disclosed |
| EP-0918789-A1 | PYRIDINE NUCLEOTIDE-DEPENDENT ENZYMES | THE UNIVERSITY OF SHEFFIELD (GB) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997048722-A1 | PYRIDINE NUCLEOTIDE-DEPENDENT ENZYMES | THE UNIVERSITY OF SHEFFIELD (GB) | 1997-12-24 | — | — | WO | disclosed |
| WO-1992010198-A1 | IMMUNOTHERAPEUTIC AGENTS, COMPOSITIONS AND METHODS | JOHNSON & JOHNSON RESEARCH PTY LIMITED (AU) | 1992-06-25 | — | — | WO | disclosed |
| EP-0090405-B1 | NOVEL AZOLE DINUCLEOTIDE COMPOUNDS AND METHODS FOR THEIR PRODUCTION | BRIGHAM YOUNG UNIVERSITY (US) | 1986-06-25 | — | — | EP | disclosed |
| US-4594415-A | Viricides | ROBINS ROLAND K (US) | 1986-06-10 | — | — | US | disclosed |
| US-4544741-A | Azole dinucleotide compounds and methods for their production | BRIGHAM YOUNG UNIVERSITY, PROVO, UT., A NONPROFIT CORP. OF UT | 1985-10-01 | — | — | US | disclosed |
| EP-0090405-A1 | Novel azole dinucleotide compounds and methods for their production | BRIGHAM YOUNG UNIVERSITY (US) | 1983-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370209-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | ADAR, CD38, PARP1 | ADORA1 22/4885ADORA3 21/4885ADORA2A 6/4885 |
| US-20250161343-A1 | METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR) | SIRT6, ADAR, SIRT1 | ADORA1 157/4885ADORA3 112/4885ADORA2A 59/4885 |
| US-12233083-B2 | Methods for the use of 5′-adenosine diphosphate ribose (ADPR) | SIRT6, ADAR, SIRT1 | ADORA1 168/4885ADORA3 125/4885ADORA2A 63/4885 |
| US-20030153559-A1 | Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof , and pharmaceutical compositions containing the same | PARP1, PARP2, PARP3 | ADORA1 268/4885ADORA3 196/4885ADORA2A 94/4885 |
| US-20250020654-A1 | SCREENING METHODS FOR PARP MODULATORS | PARP1, PARP2, PARP3 | ADORA1 2658/4885ADORA3 1428/4885ADORA2A 951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.